← All trials
NCT05003089
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2021
- Primary completion
- Dec 14, 2021
- Completion date
- Jan 25, 2022
- First posted
- Aug 12, 2021
- Last posted
- Nov 8, 2021
- Enrollment
- 48
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BayerLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.